Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 23, 2012Twelve-Month Data Presented at TCT 2012 Support Safety and Efficacy of Epic Stent in Iliac Stenting
Boston Scientific Corporation (NYSE: BSX) reports twelve-month clinical endpoint data from the ORION trial, which demonstrated robust safety and...
-
Oct 23, 2012Results Presented on Cost Effectiveness and Clinical Benefits for Older Patients of the WATCHMAN® Left Atrial Appendage Closure Device; Lotus™ Aortic Valve System Feasibility Trial Results Reviewed
Boston Scientific Corporation (NYSE: BSX) further demonstrated the strength of its structural heart program today at the 24th Annual Transcatheter...
-
Oct 18, 2012
Boston Scientific Corporation (NYSE: BSX) is scheduled to present sponsored research at the 24th Annual Transcatheter Cardiovascular Therapeutics...
-
Oct 18, 2012
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.735 billion and adjusted earnings per share of $0.16 for the third quarter ended...
-
Oct 10, 2012REPRISE II Study Results Expected to Support CE Mark and Other Regulatory Filings
Boston Scientific (NYSE: BSX) has enrolled the first patient in the REPRISE II clinical trial to evaluate the safety and performance of the Lotus™...
-
Oct 9, 2012Victory™ guidewires are designed to facilitate crossing of resistant lesions
Boston Scientific Corporation (NYSE: BSX) has begun the United States and European launch of its Victory™ guidewire, designed to facilitate crossing...
-
Oct 8, 2012Pending Addition of Next Generation Mapping and Navigation System Would Expand Company Portfolio into Complex Electrophysiology Procedures
Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement to acquire privately-held Rhythmia Medical, Inc., a developer of...
-
Oct 8, 2012
Boston Scientific Corporation (NYSE: BSX) will webcast its third-quarter 2012 financial results conference call on Thursday, October 18th, at 8:00 a.m....
-
Oct 3, 2012These Disorders Affect Nearly 30 Million American Women; New Research Shows High Prevalence of Patients Not Understanding Their Treatment Options
Boston Scientific Corporation (NYSE: BSX) is a founding member of the Pelvic Floor Disorders (PFD) Alliance, a first-of-its-kind partnership formed to...
-
Oct 2, 2012S-ICD System is the World's First and Only Commercially Available Completely Subcutaneous Implantable Defibrillator
To view the multimedia assets associated with this release, please click:...
-
Sep 28, 2012S-ICD System is the World's First and Only Commercially Available Completely Subcutaneous Implantable Defibrillator
The U.S. Food and Drug Administration has granted Boston Scientific Corporation (NYSE: BSX) regulatory approval for its S-ICD® System, the world's...
-
Sep 28, 2012
Boston Scientific Corporation (NYSE: BSX) received CE Mark approval for use of its Vercise™ Deep Brain Stimulation (DBS) System for the treatment...
-
Sep 27, 2012Next-generation balloon catheter offers enhanced deliverability and expanded options for treating coronary artery lesions
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration clearance for the Emerge™ Percutaneous Transluminal...
-
Sep 24, 2012RELIANCE® 4-FRONT™ Lead Designed to Streamline Surgical Procedure for Treatment of Heart Failure and Sudden Cardiac Arrest
Boston Scientific Corporation (NYSE: BSX) has received regulatory approval to market the RELIANCE® 4-FRONT™ lead, its next generation implantable...
-
Sep 19, 2012Company to acquire innovative, minimally invasive technologies for the treatment of coronary chronic total occlusions
Boston Scientific Corporation (NYSE: BSX) has signed a definitive agreement to acquire BridgePoint Medical, Inc., a privately held company based in...
-
Sep 19, 2012New Bronchial Thermoplasty Procedure Codes Effective January 1, 2013
The American Medical Association (AMA) Current Procedural Terminology (CPT®1) Editorial Panel has assigned Category I CPT codes specifically for...
-
Sep 6, 2012
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2012 Morgan Stanley Global Healthcare Conference on September 12th in New...
-
Aug 28, 2012
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for use of its PRECISION™ PLUS SPINAL CORD STIMULATOR (SCS) System in patients with...
-
Aug 27, 2012
PRECISION™ PLUS SPINAL CORD STIMULATOR System Receives CE Mark Approval for Peripheral Nerve Stimulation PARIS, August 27, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has...
-
Aug 26, 2012Newly Revised European Society of Cardiology Guidelines Include LAA Closure Devices
European regulators have approved an expanded indication for the Boston Scientific Corporation (NYSE: BSX) WATCHMAN® Left Atrial Appendage (LAA)...
-
Jul 27, 2012First European Implants of INGENIO™ MRI Pacemaker with New Image Ready™ Technology Performed This Week
PARIS (July 27, 2012) -- Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for use of its INGENIO™ and ADVANTIO™ pacemakers in patients in need of a magnetic resonance...
-
Jul 26, 2012
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.828 billion and adjusted earnings per share of $0.17 for the second quarter ended June...
-
Jul 18, 2012Studies Show Innovative Devices Deliver Significant Pain Relief and Reduce Lead Migration in Patients with Chronic Pain
Boston Scientific Corporation (NYSE: BSX) has presented results of two studies evaluating the Infinion™ 16 Percutaneous Lead, the world's first and...
-
Jul 12, 2012
Boston Scientific Corporation (NYSE: BSX) will webcast its second-quarter 2012 financial results conference call on Thursday, July 26, at 8:00 a.m....
-
Jul 2, 2012Milestone Marks Next Step Toward FDA Submission for Stroke Reduction Device for Patients with Atrial Fibrillation
Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the PREVAIL confirmatory study, designed to gain U.S. Food and Drug...